Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTK NASDAQ:KRYS NYSE:OGN NYSE:RCUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$49.99+0.7%$36.57$29.31▼$59.39$5.98B0.621.84 million shs4.54 million shsKRYSKrystal Biotech$150.20+0.8%$146.13$122.80▼$207.84$4.35B0.66328,033 shs252,244 shsOGNOrganon & Co.$9.80+4.1%$9.59$8.01▼$22.42$2.55B0.64.45 million shs3.93 million shsRCUSArcus Biosciences$11.64+7.7%$9.50$6.50▼$18.98$1.24B0.831.01 million shs1.12 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics+40.45%+29.93%+35.24%+53.10%-13.07%KRYSKrystal Biotech+0.88%+1.44%-5.08%+12.85%-23.64%OGNOrganon & Co.+0.11%+3.58%-3.64%-1.42%-57.92%RCUSArcus Biosciences+1.98%+4.04%+17.96%+12.67%-36.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTKCytokinetics4.1046 of 5 stars4.41.00.04.62.80.80.0KRYSKrystal Biotech4.8163 of 5 stars3.41.00.04.72.93.33.1OGNOrganon & Co.4.8008 of 5 stars3.33.01.73.72.21.73.1RCUSArcus Biosciences2.0546 of 5 stars3.41.00.00.03.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.87Moderate Buy$75.3850.80% UpsideKRYSKrystal Biotech 2.88Moderate Buy$210.3840.06% UpsideOGNOrganon & Co. 2.50Moderate Buy$18.0083.60% UpsideRCUSArcus Biosciences 2.75Moderate Buy$21.1481.67% UpsideCurrent Analyst Ratings BreakdownLatest RCUS, CYTK, KRYS, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$53.00 ➝ $71.009/3/2025CYTKCytokineticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $80.009/2/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$77.00 ➝ $84.009/2/2025CYTKCytokineticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$87.00 ➝ $96.009/2/2025CYTKCytokineticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$78.009/2/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.008/22/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$219.00 ➝ $216.008/22/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.008/8/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $77.008/7/2025RCUSArcus BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$26.00 ➝ $25.008/5/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$176.00 ➝ $166.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$18.47M323.87N/AN/A($3.08) per share-16.23KRYSKrystal Biotech$359.21M12.10$4.72 per share31.85$35.96 per share4.18OGNOrganon & Co.$6.40B0.40$5.13 per share1.91$2.82 per share3.48RCUSArcus Biosciences$258M4.80N/AN/A$5.16 per share2.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$589.53M-$5.10N/AN/AN/A-707.17%N/A-45.52%11/5/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.9230.5314.90N/A40.85%15.21%13.81%11/3/2025 (Estimated)OGNOrganon & Co.$864M$2.693.642.620.8611.15%163.88%6.99%10/30/2025 (Estimated)RCUSArcus Biosciences-$283M-$3.17N/AN/AN/A-109.56%-55.96%-25.73%11/5/2025 (Estimated)Latest RCUS, CYTK, KRYS, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CYTKCytokinetics-$1.34-$1.12+$0.22-$1.12$1.95 million$66.77 million8/6/2025Q2 2025RCUSArcus Biosciences-$1.14-$1.1053+$0.0347N/A$32.86 million$160.00 million8/5/2025Q2 2025OGNOrganon & Co.$0.94$1.00+$0.06$0.56$1.55 billion$1.59 billion8/4/2025Q2 2025KRYSKrystal Biotech$1.08$1.29+$0.21$1.29$95.42 million$96.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.82%N/A2.97%N/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ALatest RCUS, CYTK, KRYS, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/5/2025OGNOrganon & Co.quarterly$0.020.9%8/15/20258/15/20259/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokineticsN/A6.766.76KRYSKrystal BiotechN/A9.689.33OGNOrganon & Co.11.981.651.13RCUSArcus Biosciences0.184.504.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/AKRYSKrystal Biotech86.29%OGNOrganon & Co.77.43%RCUSArcus Biosciences92.89%Insider OwnershipCompanyInsider OwnershipCYTKCytokinetics3.40%KRYSKrystal Biotech13.70%OGNOrganon & Co.1.40%RCUSArcus Biosciences9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250119.66 million115.59 millionOptionableKRYSKrystal Biotech21028.94 million24.98 millionOptionableOGNOrganon & Co.4,000259.97 million256.33 millionNot OptionableRCUSArcus Biosciences500106.43 million96.21 millionOptionableRCUS, CYTK, KRYS, and OGN HeadlinesRecent News About These CompaniesRafferty Asset Management LLC Has $882,000 Position in Arcus Biosciences, Inc. $RCUSSeptember 3 at 4:29 AM | marketbeat.comNuveen LLC Takes Position in Arcus Biosciences, Inc. $RCUSSeptember 3 at 3:39 AM | marketbeat.comArcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on InflammationSeptember 2 at 4:05 PM | businesswire.comArcus Biosciences, Inc. $RCUS Shares Acquired by DAFNA Capital Management LLCSeptember 1 at 7:26 AM | marketbeat.comRussell Investments Group Ltd. Has $759,000 Stake in Arcus Biosciences, Inc. $RCUSSeptember 1 at 3:41 AM | marketbeat.comInvesco Ltd. Has $1.99 Million Stock Holdings in Arcus Biosciences, Inc. $RCUSSeptember 1 at 3:32 AM | marketbeat.comWellington Management Group LLP Acquires New Stake in Arcus Biosciences, Inc. $RCUSAugust 31 at 3:38 AM | marketbeat.comCharles Schwab Investment Management Inc. Grows Stock Position in Arcus Biosciences, Inc. $RCUSAugust 30, 2025 | marketbeat.comCampbell & CO Investment Adviser LLC Makes New $1.30 Million Investment in Arcus Biosciences, Inc. $RCUSAugust 29, 2025 | marketbeat.comSwiss National Bank Boosts Stake in Arcus Biosciences, Inc. $RCUSAugust 28, 2025 | marketbeat.comVanguard Group Inc. Has $52.50 Million Position in Arcus Biosciences, Inc. $RCUSAugust 28, 2025 | marketbeat.comArcus Biosciences, Inc. $RCUS Stock Holdings Lifted by Algert Global LLCAugust 24, 2025 | marketbeat.comArcus Biosciences, Inc. $RCUS Shares Purchased by Public Sector Pension Investment BoardAugust 24, 2025 | marketbeat.comArcus Biosciences to Participate in Three Upcoming Investor ConferencesAugust 22, 2025 | theglobeandmail.comGilead Sciences Inc. Raises Position in Arcus Biosciences, Inc. (NYSE:RCUS)August 19, 2025 | marketbeat.comJim Cramer on Arcus Biosciences: “Let This Be Your Speculation”August 16, 2025 | finance.yahoo.comCramer's Lightning Round: Uranium Energy is a buyAugust 14, 2025 | msn.comArcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from BrokeragesAugust 12, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Forecast for RCUS EarningsAugust 11, 2025 | marketbeat.comQ3 EPS Forecast for Arcus Biosciences Reduced by AnalystAugust 11, 2025 | marketbeat.comLeerink Partnrs Has Negative Estimate for RCUS Q3 EarningsAugust 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRCUS, CYTK, KRYS, and OGN Company DescriptionsCytokinetics NASDAQ:CYTK$49.99 +0.37 (+0.75%) Closing price 04:00 PM EasternExtended Trading$49.72 -0.27 (-0.53%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Krystal Biotech NASDAQ:KRYS$150.20 +1.20 (+0.81%) Closing price 04:00 PM EasternExtended Trading$150.32 +0.12 (+0.08%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Organon & Co. NYSE:OGN$9.80 +0.38 (+4.08%) Closing price 03:59 PM EasternExtended Trading$9.81 +0.01 (+0.06%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Arcus Biosciences NYSE:RCUS$11.64 +0.83 (+7.66%) Closing price 03:59 PM EasternExtended Trading$11.32 -0.32 (-2.73%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
